CN115279405A - 一种抗pd-1抗体在制备治疗肢端黑色素瘤的药物中的用途 - Google Patents
一种抗pd-1抗体在制备治疗肢端黑色素瘤的药物中的用途 Download PDFInfo
- Publication number
- CN115279405A CN115279405A CN202180019855.7A CN202180019855A CN115279405A CN 115279405 A CN115279405 A CN 115279405A CN 202180019855 A CN202180019855 A CN 202180019855A CN 115279405 A CN115279405 A CN 115279405A
- Authority
- CN
- China
- Prior art keywords
- antibody
- antigen
- pharmaceutically acceptable
- acceptable salt
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
提供一种抗PD‑1抗体与阿帕替尼在制备治疗肢端黑色素瘤的药物中的用途,该方案对肢端黑色素瘤疾病控制率达72.2%,对疾病客观缓解率为22.2%。还提供了一种抗PD‑1抗体、阿帕替尼和替莫唑胺在制备治疗黑色素瘤的药物中的用途。
Description
PCT国内申请,说明书已公开。
Claims (20)
- PCT国内申请,权利要求书已公开。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010278150 | 2020-04-10 | ||
CN2020102781504 | 2020-04-10 | ||
PCT/CN2021/000069 WO2021203769A1 (zh) | 2020-04-10 | 2021-04-09 | 一种抗pd-1抗体在制备治疗肢端黑色素瘤的药物中的用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN115279405A true CN115279405A (zh) | 2022-11-01 |
Family
ID=78023849
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202180019855.7A Pending CN115279405A (zh) | 2020-04-10 | 2021-04-09 | 一种抗pd-1抗体在制备治疗肢端黑色素瘤的药物中的用途 |
Country Status (3)
Country | Link |
---|---|
CN (1) | CN115279405A (zh) |
TW (1) | TW202144007A (zh) |
WO (1) | WO2021203769A1 (zh) |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101676267B (zh) * | 2008-09-16 | 2012-12-26 | 江苏恒瑞医药股份有限公司 | N-[4-(1-氰基环戊基)苯基]-2-(4-吡啶甲基)氨基-3-吡啶甲酰胺的盐 |
MY184154A (en) * | 2013-12-12 | 2021-03-23 | Shanghai hengrui pharmaceutical co ltd | Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof |
MX2018003306A (es) * | 2015-09-28 | 2018-05-16 | Suzhou Suncadia Biopharmaceuticals Co Ltd | Preparacion farmaceutica de anticuerpo anti-pd-1 estable y aplicacion del mismo en medicina. |
TWI764943B (zh) * | 2016-10-10 | 2022-05-21 | 大陸商蘇州盛迪亞生物醫藥有限公司 | 一種抗pd-1抗體和vegfr抑制劑聯合在製備治療癌症的藥物中的用途 |
CN108079292A (zh) * | 2016-11-23 | 2018-05-29 | 苏州盛迪亚生物医药有限公司 | 一种抗pd-1抗体在制备治疗肝癌的药物中的用途 |
CN106963948A (zh) * | 2017-05-12 | 2017-07-21 | 顾艳宏 | 阿帕替尼与Anti‑PD‑1抗体联用在制备结肠癌药物中的应用 |
-
2021
- 2021-04-09 TW TW110112949A patent/TW202144007A/zh unknown
- 2021-04-09 CN CN202180019855.7A patent/CN115279405A/zh active Pending
- 2021-04-09 WO PCT/CN2021/000069 patent/WO2021203769A1/zh active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2021203769A1 (zh) | 2021-10-14 |
TW202144007A (zh) | 2021-12-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2762746C2 (ru) | Применение комбинации антитела к pd-1 и ингибитора vegfr в изготовлении лекарственного средства для лечения злокачественных новообразований | |
CN111065411B (zh) | Pd-1抗体和vegfr抑制剂联合治疗小细胞肺癌的用途 | |
CN112512580B (zh) | Ezh2抑制剂与免疫检查点抑制剂联合在制备治疗肿瘤的药物中的用途 | |
CN112007162B (zh) | Ezh2抑制剂与免疫检查点抑制剂、vegfr抑制剂联合在制备治疗肿瘤药物中的用途 | |
WO2018072743A1 (zh) | Pd-1抗体与ido抑制剂联合在制备抗肿瘤的药物中的用途 | |
WO2021063340A1 (zh) | Ezh2抑制剂与免疫检查点抑制剂、酪氨酸激酶抑制剂联合在制备治疗肿瘤药物中的用途 | |
WO2020239085A1 (zh) | 治疗黑色素瘤的联用药物组合物 | |
CN112955148B (zh) | Cdk4/6抑制剂联合免疫治疗在制备治疗淋巴瘤的药物中的用途 | |
WO2021057764A1 (zh) | Pd-1抗体联合紫杉类化合物在制备治疗三阴性乳腺癌的药物中的用途 | |
CN115279405A (zh) | 一种抗pd-1抗体在制备治疗肢端黑色素瘤的药物中的用途 | |
CN113491769A (zh) | 药物联合 | |
CN110680919A (zh) | Cdk4/6抑制剂联合免疫治疗在制备治疗肿瘤的药物的用途 | |
CN110812485A (zh) | 抗pd-1抗体联合化学疗法在制备治疗肿瘤的药物中的用途 | |
TWI822897B (zh) | 一種抗pd-1抗體和法米替尼聯合在製備治療腫瘤的藥物中的用途 | |
CN114099670A (zh) | 酪氨酸激酶抑制剂与抗pd-1抗体联合在制备治疗肿瘤药物中的用途 | |
CN117085123A (zh) | 抗PD-L1抗体和c-Met激酶抑制剂的药物组合 | |
CN114667159A (zh) | 喹啉衍生物与pd-1单抗的药物组合 | |
KR20240046526A (ko) | 소세포폐암 치료용 약학적 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |